Hair loss treatment with beta-sitosterole vessicles


Permalink 11:08:06 am, by mdst, 275 words, 3754 views   English (US)
Categories: Announcements [A]

Hair loss treatment with beta-sitosterole vessicles

Arch Dermatol Res. 2011 Dec 13. [Epub ahead of print]

Development and characterization of phyto-vesicles of â-sitosterol for the treatment of androgenetic alopecia.

Upadhyay K, et al


Alopecia or hair loss is a psychologically distressing phenomenon. Androgenetic alopecia (AGA) is the most common form of hair loss, which affects millions of men and women worldwide, and is an androgen driven disorder. To study the effect of â-sitosterol phyto-vesicles on AGA, the testosterone-induced alopecia model was used. For the study, the albino rats were used and the period of study was 21 days. â-Sitosterol is a phytosterol which is chemically similar to cholesterol. This compound was found suitable for the preparation of phyto-vesicles by the process involving its complexation with phosphatidyl choline. Pharmacokinetic studies of â-sitosterol reveal its poor absorption through the intestine. The objective of the present study is to enhance the bioavailability of â-sitosterol by its complexation with phosphatidyl choline and then to formulate it as phyto-vesicles for the treatment of hair loss. The complex of â-sitosterol was prepared with phosphatidyl choline and characterized on the basis of solubility, melting point, TLC, UV, IR and NMR spectroscopy. This complex was then formulated as phyto-vesicles and then characterized. The results revealed that effect on alopecia is better in case of phyto-vesicles as compared to the complex, physical mixture and the â-sitosterol itself. Enhanced bioavailability of the â-sitosterol complex may be due to the amphiphilic nature of the complex, which greatly enhance the water and lipid solubility of the compound. The present study clearly indicates the superiority of phyto-vesicles over the complex and â-sitosterol, in terms of better absorption and improved activity for the treatment of hair loss.


No Pingbacks for this post yet...

Hair Loss

Hair Loss and Hair loss treatment




  • Cormorbid conditions in Alopecia Areata

    JAMA Dermatol. 2013 May 22:1-5. doi: 10.1001/jamadermatol.2013.3049. [Epub ahead of print]

    Autoimmune, Atopic, and Mental Health Comorbid Conditions Associated With Alopecia Areata in the United States.

    Huang KP, Mullangi S, Guo Y, Qureshi AA.


    OBJECTIVE To evaluate the prevalence of comorbid conditions among patients with alopecia areata (AA) seen at tertiary care hospitals in Boston, Massachusetts, during an 11-year period. DESIGN Retrospective cross-sectional study. SETTING Tertiary care hospitals in Boston, including Brigham and Women's Hospital and Massachusetts General Hospital. PARTICIPANTS We identified 3568 individuals with AA seen in the Partners health care system in Boston between January 1, 2000, and January 1, 2011. We performed comprehensive searches of the Research Patient Data Repository using International Classification of Diseases, Ninth Revision code 704.01. We randomly selected 350 patients and manually reviewed their medical records to train and validate a novel artificial intelligence program. This program then used natural language processing to review free-text medical records and confirm a diagnosis of AA. To confirm the algorithm, we manually reviewed a subset of records and found 93.9% validity. MAIN OUTCOMES AND MEASURES The prevalence of comorbid conditions was assessed. RESULTS Common comorbid conditions included autoimmune diagnoses (thyroid disease in 14.6%, diabetes mellitus in 11.1%, inflammatory bowel disease in 6.3%, systemic lupus erythematosus in 4.3%, rheumatoid arthritis in 3.9%, and psoriasis and psoriatic arthritis in 2.0%), atopy (allergic rhinitis, asthma, and/or eczema in 38.2% and contact dermatitis and other eczema in 35.9%), and mental health problems (depression or anxiety in 25.5%). We also found high prevalences of hyperlipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%). This profile was different from that seen in a comparison psoriasis and psoriatic arthritis group. CONCLUSIONS AND RELEVANCE We found a high prevalence of comorbid conditions among individuals with AA presenting to academic medical centers in Boston. Physicians caring for patients with AA should consider screening for comorbid conditions.

    Modiefied for hair loss treatment and hair regrowth blog use


    Hair Loss and Hair Loss Treatment

  • Permalink
  • drp hair loss site

    Hair Loss Treatment

  • Permalink
  • Gohair loss site Permalink
  • blog Permalink
  • enough said.

  • Hair-raising. The latest news on male-pattern baldness.

    Adv Nurse Pract. 1999 Apr;7(4):39-42, 83. Hair-raising. The latest news on male-pattern baldness.
    Proctor PH.

    The initiating event in balding seems to be an abnormal sensitivity to the male sex hormones. In addition, a multifactorial model is emerging in which hormones affect the hair follicle in a way that causes it to be perceived as a foreign body by the immune system, which then mounts an attack. Several new classes of agents have the potential to treat hair loss. More than 40 U.S. and several hundred foreign patents have been issued for hair-loss treatment agents. As is common in dermatology, no single agent works universally against hair loss, so the treatment process is often one of trial and error.

    This is a paper by Dr. Proctor

  • nitrone blog Permalink


XML Feeds

What is RSS?

Who's Online?

  • Guest Users: 3

powered by b2evolution free blog software